Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15601913 | 0.87 | SLC7A5 (0.44) | KMT2AMEN1FOLH1SLC7A5PPARG | |
| SCHEMBL15592547 | 0.87 | FOLH1 (0.49) | KMT2AMEN1FOLH1SLC7A5PPARG | |
| SCHEMBL1692133 | 0.80 | KMT2A (0.47) | KMT2AMEN1SLC7A5PPARGBCL2 | |
| SCHEMBL15108901 | 0.79 | KMT2A (0.58) | KMT2AMEN1PPARGBCL2L3MBTL1 | |
| SCHEMBL14117419 | 0.76 | KMT2A (0.58) | KMT2AMEN1PPARGBCL2L3MBTL1 | |
| SCHEMBL322040 | 0.76 | KMT2A (0.53) | KMT2AMEN1SLC7A5PPARGBCL2 | |
| SCHEMBL15676710 | 0.76 | KMT2A (0.82) | KMT2AMEN1L3MBTL1HSD17B1HSD17B2 | |
| SCHEMBL15592546 | 0.75 | SLC7A5 (0.45) | KMT2AMEN1FOLH1SLC7A5PPARG | |
| SCHEMBL16301365 | 0.74 | KMT2A (0.53) | KMT2AMEN1BCL2PTGS2L3MBTL1 | |
| SCHEMBL15601880 | 0.74 | PPARG (0.52) | KMT2AMEN1SLC7A5PPARGBCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062028-B2 | Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | GRK5, GPBAR1, GPR55 | KMT2A 2045/4885MEN1 3428/4885FOLH1 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.